Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine
- 1 January 1994
- journal article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 21 (1) , 46-52
- https://doi.org/10.1007/bf00182305
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia.1993
- Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.1992
- Therapeutic use of [131I]metaiodobenzylguanidine in neuroblastoma: a phase II study in 26 patients. "Société Française d'Oncologie Pédiatrique" and Nuclear Medicine Co-investigators.1991
- Long-term results of [131I]metaiodobenzylguanidine treatment of refractory advanced neuroblastoma.1991
- Experience with palliative [131I]metaiodobenzylguanidine therapy in advanced neuroblastoma.1991
- Preoperative [131I]metaiodobenzylguanidine therapy of neuroblastoma at diagnosis ("MIBG de novo").1991
- Treatment of neuroblastoma with [131I]metaiodobenzylguanidine: long-term results in 25 patients.1991
- Outcome of [131I]metaiodobenzylguanidine therapy of neuroblastoma: seven years after.1991
- [131I]metaiodobenzylguanidine in neuroblastoma patients at diagnosis.1991
- Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma.1991